The results so far are encouraging as all trials show manageable toxicity (mostly lower grade adverse effects and no ‘on target/off tumor’ toxicities), thereby confirming MSLN as a promising target for CAR T cell therapy against MM. This evidence concerns the gene MSLN and neoplasm.